圣湘生物跌6.56% 上市即巅峰超募13亿西部证券保荐

Group 1 - The core point of the article is that Shengxiang Biotechnology (688289.SH) is currently experiencing a decline in stock price, closing at 20.67 yuan with a drop of 6.56%, indicating a state of being below its initial public offering (IPO) price [1] - Shengxiang Biotechnology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 28, 2020, with an issuance of 40 million shares at an IPO price of 50.48 yuan per share [1] - The highest price recorded for Shengxiang Biotechnology since its listing was 155.55 yuan on the first trading day [1] Group 2 - The total amount of funds raised by Shengxiang Biotechnology was 201.92 million yuan, with a net amount of 186.93 million yuan, exceeding the original plan by 131.27 million yuan [1] - The company planned to use the raised funds for projects including the production base for precision intelligent molecular diagnostic systems, upgrading the research and development center, and enhancing the marketing network and information technology [1] - The listing expenses for Shengxiang Biotechnology amounted to 150 million yuan, with underwriting fees to the lead underwriters, Western Securities and CITIC Securities, totaling 128 million yuan [2] Group 3 - On May 26, 2022, Shengxiang Biotechnology announced a profit distribution plan for the year 2021, proposing a cash dividend of 3.75 yuan (including tax) for every 10 shares held, along with a capital reserve conversion of 4.8 shares for every 10 shares [2]